Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension

Satoshi Akagi, Kazufumi Nakamura, Katsumasa Miyaji, Aiko Ogawa, Kengo Fukushima Kusano, Hiroshi Itoh, Hiromi Matsubara

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Background: The appropriate dose range of epoprostenol is thought to be 25-40 ng · kg-1 · min-1 based on the results of previous studies showing that epoprostenol therapy reduced mean pulmonary artery pressure (mPAP) by 12-22% and pulmonary vascular resistance (PVR) by 32-53% compared with baseline values in patients with idiopathic pulmonary arterial hypertension (IPAH). However, the efficacy of treatment of IPAH patients with epoprostenol >40 ng · kg-1 · min-1 has not been determined and this was the aim of the present study. Methods and Results: The study group comprised 16 consecutive patients, none of whom died; 2 dropped out because they could not be titrated up as needed to the highest effective epoprostenol dose. Hemodynamics were evaluated in 14 IPAH patients who received high-dose epoprostenol monotherapy. The mean epoprostenol dosage was 107±40 ng · kg-1 · min-1 (range, 54-190 ng · kg-1 · min-1) and the mean duration of high-dose epoprostenol therapy was 1,355±627 days (range, 582-2,410 days). Significant decreases from baseline values were seen in mPAP (from 66±16 to 47±12 mmHg, P

Original languageEnglish
Pages (from-to)2200-2205
Number of pages6
JournalCirculation Journal
Volume74
Issue number10
DOIs
Publication statusPublished - 2010

Fingerprint

Epoprostenol
Hemodynamics
Pulmonary Artery
Therapeutics
Pressure
Familial Primary Pulmonary Hypertension
Vascular Resistance

Keywords

  • Epoprostenol
  • Idiopathic pulmonary arterial hypertension
  • Prostacyclin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension. / Akagi, Satoshi; Nakamura, Kazufumi; Miyaji, Katsumasa; Ogawa, Aiko; Kusano, Kengo Fukushima; Itoh, Hiroshi; Matsubara, Hiromi.

In: Circulation Journal, Vol. 74, No. 10, 2010, p. 2200-2205.

Research output: Contribution to journalArticle

Akagi, Satoshi ; Nakamura, Kazufumi ; Miyaji, Katsumasa ; Ogawa, Aiko ; Kusano, Kengo Fukushima ; Itoh, Hiroshi ; Matsubara, Hiromi. / Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension. In: Circulation Journal. 2010 ; Vol. 74, No. 10. pp. 2200-2205.
@article{d5344602fd524975b28c2b9264b76059,
title = "Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension",
abstract = "Background: The appropriate dose range of epoprostenol is thought to be 25-40 ng · kg-1 · min-1 based on the results of previous studies showing that epoprostenol therapy reduced mean pulmonary artery pressure (mPAP) by 12-22{\%} and pulmonary vascular resistance (PVR) by 32-53{\%} compared with baseline values in patients with idiopathic pulmonary arterial hypertension (IPAH). However, the efficacy of treatment of IPAH patients with epoprostenol >40 ng · kg-1 · min-1 has not been determined and this was the aim of the present study. Methods and Results: The study group comprised 16 consecutive patients, none of whom died; 2 dropped out because they could not be titrated up as needed to the highest effective epoprostenol dose. Hemodynamics were evaluated in 14 IPAH patients who received high-dose epoprostenol monotherapy. The mean epoprostenol dosage was 107±40 ng · kg-1 · min-1 (range, 54-190 ng · kg-1 · min-1) and the mean duration of high-dose epoprostenol therapy was 1,355±627 days (range, 582-2,410 days). Significant decreases from baseline values were seen in mPAP (from 66±16 to 47±12 mmHg, P",
keywords = "Epoprostenol, Idiopathic pulmonary arterial hypertension, Prostacyclin",
author = "Satoshi Akagi and Kazufumi Nakamura and Katsumasa Miyaji and Aiko Ogawa and Kusano, {Kengo Fukushima} and Hiroshi Itoh and Hiromi Matsubara",
year = "2010",
doi = "10.1253/circj.CJ-10-0190",
language = "English",
volume = "74",
pages = "2200--2205",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "10",

}

TY - JOUR

T1 - Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension

AU - Akagi, Satoshi

AU - Nakamura, Kazufumi

AU - Miyaji, Katsumasa

AU - Ogawa, Aiko

AU - Kusano, Kengo Fukushima

AU - Itoh, Hiroshi

AU - Matsubara, Hiromi

PY - 2010

Y1 - 2010

N2 - Background: The appropriate dose range of epoprostenol is thought to be 25-40 ng · kg-1 · min-1 based on the results of previous studies showing that epoprostenol therapy reduced mean pulmonary artery pressure (mPAP) by 12-22% and pulmonary vascular resistance (PVR) by 32-53% compared with baseline values in patients with idiopathic pulmonary arterial hypertension (IPAH). However, the efficacy of treatment of IPAH patients with epoprostenol >40 ng · kg-1 · min-1 has not been determined and this was the aim of the present study. Methods and Results: The study group comprised 16 consecutive patients, none of whom died; 2 dropped out because they could not be titrated up as needed to the highest effective epoprostenol dose. Hemodynamics were evaluated in 14 IPAH patients who received high-dose epoprostenol monotherapy. The mean epoprostenol dosage was 107±40 ng · kg-1 · min-1 (range, 54-190 ng · kg-1 · min-1) and the mean duration of high-dose epoprostenol therapy was 1,355±627 days (range, 582-2,410 days). Significant decreases from baseline values were seen in mPAP (from 66±16 to 47±12 mmHg, P

AB - Background: The appropriate dose range of epoprostenol is thought to be 25-40 ng · kg-1 · min-1 based on the results of previous studies showing that epoprostenol therapy reduced mean pulmonary artery pressure (mPAP) by 12-22% and pulmonary vascular resistance (PVR) by 32-53% compared with baseline values in patients with idiopathic pulmonary arterial hypertension (IPAH). However, the efficacy of treatment of IPAH patients with epoprostenol >40 ng · kg-1 · min-1 has not been determined and this was the aim of the present study. Methods and Results: The study group comprised 16 consecutive patients, none of whom died; 2 dropped out because they could not be titrated up as needed to the highest effective epoprostenol dose. Hemodynamics were evaluated in 14 IPAH patients who received high-dose epoprostenol monotherapy. The mean epoprostenol dosage was 107±40 ng · kg-1 · min-1 (range, 54-190 ng · kg-1 · min-1) and the mean duration of high-dose epoprostenol therapy was 1,355±627 days (range, 582-2,410 days). Significant decreases from baseline values were seen in mPAP (from 66±16 to 47±12 mmHg, P

KW - Epoprostenol

KW - Idiopathic pulmonary arterial hypertension

KW - Prostacyclin

UR - http://www.scopus.com/inward/record.url?scp=77958036618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958036618&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-10-0190

DO - 10.1253/circj.CJ-10-0190

M3 - Article

C2 - 20697180

AN - SCOPUS:77958036618

VL - 74

SP - 2200

EP - 2205

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 10

ER -